ClinicalTrials.gg
RecruitingNCT06506617HCAPPED-IUpdated Jul 17, 2024

HCAPPED I: HCAP-Pcr in Emergency Department

An observational study in Pneumonia, Bronchoalveolar Lavage and Antimicrobial Treatment, sponsored by Azienda Ospedaliero-Universitaria Careggi. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-17.

Sponsored by Azienda Ospedaliero-Universitaria Careggi · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
93
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Pneumonia with a site in Italy — 19 open to participants now, 20 under way, 4 of them phase 3. Pneumonia · Italy.

Planned enrollment
27th of 37
93 · median 246
Started
2024
with 7 others
Observational
37 of 83
10 open now
Primary completion
2025-07
later than 8 of 19 live
Registered
72nd of 83
by date
Lead sponsor
4 of 83
Azienda Ospedaliero-Universitaria Careggi

Among the 83 studies in Pneumonia with a site in Italy, this one is the 27th largest by planned enrollment of the 37 observational ones that give a count, is one of 8 that started in 2024, is one of 37 observational ones, reaches primary completion later than 8 of the 19 other live ones, and was the 72nd registered.

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

19 of the 83 studies in Pneumonia with a site in Italy are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Pneumonia with a site in Italy, or all of them as a file.
02

Study summary

Prospective Observational Study (on Diagnostic Procedure) - Single-Center, Non-Profit.

A pilot study will be conducted on a prospective cohort of patients with HCAP (Healthcare-Associated Pneumonia). This study will be conducted on a single arm of patients. No control group or randomization is planned.

The use of syndromic molecular panels in pneumonias with risk factors for MDR (multidrug-resistant) pathogens, such as in patients with HCAP, has become common practice. However, the use of this tool is reserved for patients with severe forms of HCAP (PIRO>2, at least moderate ARDS, and respiratory failure requiring high-flow oxygen during sepsis) (30), and it is not yet standardized by international guidelines. The decision to use this tool or not is currently at the clinician\'s discretion and is usually reserved for the severe forms mentioned above. The study aims to determine if the early use of this tool has a real benefit on the management of antibiotic therapy for these patients in terms of therapeutic changes compared to corporate and international guidelines.

Duration of patient enrollment: 1 year. Duration of the study: 1.5 years.

03

Conditions studied

  • Pneumonia
  • Bronchoalveolar Lavage
  • Antimicrobial Treatment
  • Sputum

Browse trials for

Keywords

  • Bronchoalveolar lavage
  • Endotracheal Aspirate
  • Antimicrobial treatment
  • pneumonia
  • hcap
  • pcr multiplex
  • moleculas syndromic panel
  • bal
  • bas
  • eta
  • sputum
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients over the age of 18 who undergo bronchoalveolar lavage (BAL) in the Emergency Department (DEA), with a Rankin score of less than 5, and who are admitted to the Emergency Department with a diagnosis of healthcare-associated pneumonia (HCAP) of bacterial, viral, or fungal origin.

A patient is considered to have HCAP if they meet any of the following conditions:

Hospitalized in an acute care hospital for two or more days within 90 days of symptom onset Residing in a nursing home or long-term care facility Received intravenous antibiotic therapy, chemotherapy, or wound care within the past 30 days Attended a hospital or hemodialysis clinic within the past 30 days for medical reasons, visits, or day services

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All patients over the age of 18 who undergo bronchoalveolar lavage (BAL) in the Emergency Department (DEA), with a Rankin score of less than 5, and who are admitted to the Emergency Department with a diagnosis of healthcare-associated pneumonia (HCAP) of bacterial, viral, or fungal origin. The diagnosis must be confirmed by clinical and radiological criteria according to the IDSA guidelines, which include: New pulmonary infiltrate on chest X-ray, Evidence that the infiltrate is of infectious origin, At least two of the following three clinical signs: Fever higher than 38 °C, Leukocytosis or leukopenia, Purulent secretions.

Additionally, patients must meet at least one of the following criteria:

  • Need for high-flow oxygen therapy (VM35 or FiO2 >35%, Reservoir, HFNC, NIV, CPAP)
  • Intubation (IOT)
  • SOFA score ≥2 or PSI score >85 (age 75 + IR)
  • Horowitz index (PaO2/FiO2) \< 200

Exclusion criteria

Exclusion Criteria:

  • Lack of consent
  • Age under 18 or over 90
  • Pregnancy
  • less than 3 months
  • Hospital admission >48 hours (hospital-acquired pneumonia - HAP)
  • Rankin score ≥ 5
  • Community-acquired pneumonia (CAP)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
93 participants (estimated)
Target follow-up
90 Days
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • PCR multiplex (BIOFIRE® FILMARRAY® Pneumonia plus Panel)

    The study seeks to assess the utility of molecular diagnostic tests in the emergency department for the microbiological etiological diagnosis of healthcare-associated pneumonia (HCAP). In clinical practice, patients with respiratory and infectious symptoms undergo blood sample collection for blood gas, chemical-physical, and culture analyses, urine samples for urinary antigen testing, and imaging diagnostics (X-ray, CT, ultrasound). Due to local infection control and surveillance measures, all patients with respiratory symptoms undergo a nasopharyngeal antigen test for SARS-CoV-2 as part of standard clinical practice. After completing the diagnostic work-up and diagnosing HCAP pneumonia, endobronchial samples are typically collected for multiplex PCR testing (BIOFIRE® FILMARRAY® Pneumonia plus Panel). Patients from whom these samples are collected are those needing high-flow oxygen therapy (VM35 or FiO2 higher, Reservoir, HFNC, NIV, CPAP), undergoing IOT, SOFA ≥2, PaO2/FiO2 \< 200, o

06

What researchers measure

Primary outcomes

  1. evaluate the impact of early use of multiplex PCR

    The primary objective of the study is to evaluate the impact of early use of multiplex PCR on empirical antibiotic therapy. This will be measured by considering the percentage of cases in which the use of multiplex PCR alters the therapy ('escalation' and 'de-escalation') compared to local empirical antibiotic therapy guidelines within 24 hours of hospital admission.

    Time frame: perioperatively/periprocedurally

Secondary outcomes

  1. Time to Antibiotic Escalation or De-escalation

    Measure the time from hospital admission to the escalation or de-escalation of antibiotic therapy.

    Time frame: up to 3 months

  2. Length of Hospital Stay

    Assess the total duration of the hospital stay.

    Time frame: up to 3 months

  3. Need for Escalation of Supportive Therapy:

    Evaluate the necessity for increased supportive therapy, defined as: a) Need for invasive or non-invasive ventilation b) Transfer to a higher level of care c) In-hospital mortality from any cause (complicated course)

    Time frame: up to 3 months

  4. Duration of Antibiotic Therapy:

    Track the length of time antibiotics are administered.

    Time frame: up to 3 months

  5. De-escalation of Antibiotic Therapy

    Assess the de-escalation of antibiotic therapy within the first 7 days of inclusion in the study.

    Time frame: 7 days from admission

  6. Escalation of Antibiotic Therapy

    Assess the escalation of antibiotic therapy within the first 7 days of inclusion in the study.

    Time frame: 7 days from admission

  7. Identification of HCAP Etiology

    Determine the cause of HCAP within the first 7 days of inclusion using all methods: multiplex PCR, culture tests, antigen detection, and serology.

    Time frame: 7 days from admission

  8. In-hospital Mortality

    Measure in-hospital mortality rates for pneumonia and all causes.

    Time frame: up to 3 months

  9. 30-day Mortality and Readmission

    Measure mortality rates for pneumonia and all causes, and track readmissions within 30 days.

    Time frame: 30 days from discharge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jul 2025, 13 months after the start.

Of 210 non-industry observational studies under Pneumonia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 13 months is below that.

Counting every sponsor, half of 223 studies reached it within 27 months; a quarter within 13 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Jul 17, 2024
StartActual
Jun 7, 2024
Primary completionEst.
Jul 7, 2025
CompletionEst.
Jan 7, 2026
Last update
Jul 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06506617
Lead sponsor
Azienda Ospedaliero-Universitaria Careggi
Responsible party
Peiman Nazerian (Principal Investigator, Azienda Ospedaliero-Universitaria Careggi) — Principal investigator
First posted
Jul 17, 2024
Start date
Jun 7, 2024
Primary completion
Jul 7, 2025 (estimated)
Completion
Jan 7, 2026 (estimated)
Last update
Jul 17, 2024

Study contacts

Pelagatti Lorenzo, Dr
Contact
pelagattil@aou-careggi.toscana.it
+393385917317
Pelagatti Lorenzo, Dr
Contact
lorenzo.pelagatti@unifi.it
+390557947088
Pelagatti Lorenzo, Dr
principal investigator · AOU Careggi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion